Open-label, randomized multicenter phase II clinical trial of a toll-like receptor-2 agonist mycobacterium w (Cadi-05) in combination with paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced non-small cell lung cancer.

Trial Profile

Open-label, randomized multicenter phase II clinical trial of a toll-like receptor-2 agonist mycobacterium w (Cadi-05) in combination with paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2011

At a glance

  • Drugs Cadi 05 (Primary) ; Cisplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 30 Jun 2011 New trial record
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top